The estimated Net Worth of Robert S Radie is at least 284 千$ dollars as of 15 February 2019. Mr. Radie owns over 3,750 units of Rockwell Medical Inc stock worth over 27,675$ and over the last 10 years he sold RMTI stock worth over 256,635$. In addition, he makes 0$ as Independent Director at Rockwell Medical Inc.
Sign up
Mr. Radie RMTI stock SEC Form 4 insiders trading
Robert has made over 4 trades of the Rockwell Medical Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 3,750 units of RMTI stock worth 26,775$ on 15 February 2019.
The largest trade he's ever made was selling 15,000 units of Rockwell Medical Inc stock on 3 October 2016 worth over 112,050$. On average, Robert trades about 1,313 units every 34 days since 2015. As of 15 February 2019 he still owns at least 6,750 units of Rockwell Medical Inc stock.
You can see the complete history of Mr. Radie stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Radie biography
Robert S. Radie serves as Independent Director of the Company. He has been a director since March 2020. He served as President and Chief Executive Officer and a member of the board of directors of Zyla Life Sciences, a life sciences company, from March 2012 to October 2019. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company. From March 2009 to November 2010, Mr. Radie served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie has been a member of the board of directors of Paratek Pharmaceuticals since November 2014, and has also served as a director of Life Sciences Pennsylvania, a life sciences industry group, since January 2016 and Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, since 2006. He previously served as a member of the board of directors of Veloxis Pharmaceuticals A/S from June 2016 to February 2020 and Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014. Mr. Radie received his B.S. in Chemistry from Boston College.
How old is Robert Radie?
Robert Radie is 56, he's been the Independent Director of Rockwell Medical Inc since 2020. There are 12 older and 4 younger executives at Rockwell Medical Inc. The oldest executive at Rockwell Medical Inc is Dr. Russell H. Ellison M.Sc., M.D., MSc., 73, who is the Pres, CEO & Director.
What's Robert Radie's mailing address?
Robert's mailing address filed with the SEC is C/O ROCKWELL MEDICAL, INC., 30142 WIXOM ROAD, WIXOM, MI, 48393.
Insiders trading at Rockwell Medical Inc
Over the last 21 years, insiders at Rockwell Medical Inc have traded over 3,082,721$ worth of Rockwell Medical Inc stock and bought 689,891 units worth 3,959,861$ . The most active insiders traders include Robert L Chioini、David S.Rbi Private Investm...、Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of 170,433$. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth 43,724$.
What does Rockwell Medical Inc do?
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
What does Rockwell Medical Inc's logo look like?
Complete history of Mr. Radie stock trades at Paratek Pharmaceuticals、Rockwell Medical Inc
Rockwell Medical Inc executives and stock owners
Rockwell Medical Inc executives and other stock owners filed with the SEC include:
-
Raymond Pratt,
Chief Development Officer -
Ajay Gupta,
Chief Scientific Officer -
Dr. Russell H. Ellison M.Sc., M.D., MSc.,
Pres, CEO & Director -
Dr. Raymond Dennis Pratt FACP, M.D.,
Chief Devel. Officer -
Russell L. Skibsted M.B.A.,
Exec. VP, CFO & Chief Bus. Officer -
John Cooper,
Independent Director -
Mark Ravich,
Independent Director -
John McLaughlin,
Independent Chairman of the Board -
Robert Radie,
Independent Director -
Marc Hoffman,
Chief Medical Officer -
Michael DeYoung,
Vice President - Operations -
Paul McGarry,
Principal Accounting Officer, Vice President, Corporate Controller -
Jim McCarthy,
Senior Vice President - Corporate and Business Development -
Russell Skibsted,
Executive Vice President, Chief Financial Officer and Chief Business Officer -
Russell Ellison,
President, Chief Executive Officer, Director -
David J. Kull,
Sec. -
Dr. Marc L. Hoffman,
Chief Medical Officer -
Timothy T. Chole,
Sr. VP of Sales & Marketing -
Megan C. Timmins,
Sr. VP, Gen. Counsel & Corp. Sec. -
Paul E. McGarry,
VP, Corp. Controller & Principal Accounting Officer -
Tim Chole,
VP of Marketing -
Anne Boardman,
VP of Sales and Strategic Accounts -
James A. McCarthy,
Sr. VP of Bus. & Corp. Devel. -
Michael Costello,
Gen. Counsel -
David S.Rbi Private Investm...,
-
Patrick J Bagley,
Director -
Ronald D Boyd,
Director -
Robin L Smith,
Director -
Kenneth L Holt,
Director -
Allen Nissenson,
Director -
Stuart M Paul,
Chief Executive Officer -
Brothers, Inc.Richmond Davi...,
-
Benjamin Wolin,
Director -
Lisa N Colleran,
Director -
Mark H Ravich,
Director -
David Kull,
Principal Accounting Officer -
David S.Rbi Private Investm...,
-
Angus W. Smith,
Chief Financial Officer -
David S.Rbi Private Investm...,
-
Mark Strobeck,
President and CEO -
David A Hagelstein,
10% owner -
Annamaria T Kausz,
VP of Drug Development -
Robert L Chioini,
Chairman, President and CEO -
Richard C Yocum,
VP - Clin. Dev. & Med. Affairs -
Thomas E Klema,
Vice President, CFO -
Megan C. Timmins,
EVP, CLO and Secretary -
David S.Rbi Private Investm...,
-
Joan Lau,
Director -
Jesse Neri,
SVP, FINANCE